Novo Nordisk A/S
XBER:NOV
Novo Nordisk A/S
XBER:NOV
Price:
43.99
EUR
Market Closed
Market Cap:
€149.4B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
N
|
Novo Nordisk A/S
XBER:NOV
|
DK |
|
DHI Group Inc
NYSE:DHX
|
US |
|
A
|
AUX International Holdings Ltd
HKEX:2080
|
HK |
|
LXRandCo Inc
TSX:LXR
|
CA |
|
R
|
RGB International Bhd
KLSE:RGB
|
MY |
|
Luxfer Holdings PLC
NYSE:LXFR
|
UK |
|
A
|
Ams Public Transport Holdings Ltd
HKEX:77
|
HK |
|
Ceres Global Ag Corp
TSX:CRP
|
US |
|
C
|
Centerra Gold Inc
NYSE:CGAU
|
CA |
|
O
|
Opus Global Nyrt
BET:OPUS
|
HU |
|
T
|
Tamburi Investment Partners SpA
LSE:0G9J
|
IT |
|
T
|
Tracxn Technologies Ltd
NSE:TRACXN
|
IN |
|
B
|
Black Spade Acquisition II Co
NASDAQ:BSII
|
HK |
|
Shaftesbury PLC
LSE:SHB
|
UK |
|
Khandwala Securities Ltd
NSE:KHANDSE
|
IN |
|
Log-in Logistica Intermodal SA
BOVESPA:LOGN3
|
BR |
Multiples-Based Value
The
Multiples-Based Value for
Novo Nordisk A/S (NOV)
under the Base Case is
hidden
EUR.
Compared with the current market price of 43.99 EUR, the stock appears
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
NOV Multiples-Based Value
LOCKED
Multiples Across Competitors
NOV Competitors Multiples
Novo Nordisk A/S Competitors
Novo Nordisk A/S Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DK |
|
Novo Nordisk A/S
XBER:NOV
|
1.1T EUR | 3.4 | 10.3 | 7.6 | 9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883.9B USD | 13.6 | 42.8 | 28.9 | 30.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.2B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP | 5.4 | 31.2 | 17.2 | 24.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD | 4.6 | 16.4 | 10.1 | 12.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 5.4 | 21.8 | 13.5 | 17.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161B USD | 2.6 | 20.7 | 7.9 | 10.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120B USD | 2.5 | 17 | 7.2 | 8.8 | |
| UK |
|
GSK plc
XETRA:GS71
|
100.1B EUR | 2.6 | 15.1 | 8.3 | 10.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
